Stemline Therapeutics Inc (STML) 14.07 $STML
Stemline Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 04, 7:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 17 Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015 at 10:00 AM ET. The conference will be held at The Waldorf-Astoria in New York, NY. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
STML: 14.07 (-0.10)
3 Biotech Stocks You Won't Want To Miss In 2015
BPD Research - at Seeking Alpha - Fri Jan 30, 10:30AM CST
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), STML: 14.07 (-0.10)
Stemline Therapeutics Announces SL-701 Granted Orphan Drug Designation for the Treatment of Glioma
GlobeNewswire - Fri Jan 30, 7:36AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics targeting cancer stem cells (CSCs) and tumor bulk, announced today that SL-701 has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of glioma.
STML: 14.07 (-0.10)
Stemline Therapeutics (STML) Crumbles: Stock Falls by 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 7:44AM CST
Stemline Therapeutics (STML) fell nearly 10% in the last trading session amid huge volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
STML: 14.07 (-0.10)
Nasdaq stocks posting largest percentage decreases
AP - Thu Jan 08, 12:18PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ENPH: 15.15 (+0.37), PODD: 32.00 (-0.07), BWEN: 5.48 (+0.15), WATT: 9.43 (+0.01), RDEN: 16.59 (+0.90), MARPS: 11.70 (+0.10), BRID: 7.55 (-0.04), ICPT: 209.12 (+7.12), AIRT: 19.45 (+0.39), INFI: 15.13 (+0.55), JST: 5.35 (+0.14), STML: 14.07 (-0.10)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 11:47AM CST
ELOS: 10.16 (+0.07), MBII: 3.88 (+0.33), PDFS: 18.31 (+0.04), CASM: 1.36 (-0.01), PHMD: 1.68 (+0.04), EPRS: 7.67 (+0.67), BIND: 6.06 (+0.21), JOB: 0.79 (+0.01), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), ARO: 3.63 (+0.04), PODD: 32.00 (-0.07), AOI: 1.05 (+0.03), BWEN: 5.48 (+0.15), NBIX: 37.22 (+0.27), VLCCF: 4.15 (-0.06), NEFF: 10.43 (-0.04), PSTR: 4.63 (+0.14), INFI: 15.13 (+0.55), APOL: 25.97 (+0.33)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:15AM CST
NRX: 6.67 (-0.14), BIND: 6.06 (+0.21), NBG: 1.61 (+0.18), MBT: 10.36 (+0.62), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), SIG: 120.19 (+0.36), PBR: 6.98 (+0.44), NBIX: 37.22 (+0.27), PIR: 12.52 (+0.17), VLCCF: 4.15 (-0.06), CONN: 24.69 (-0.07), CYTR: 2.96 (+0.23), PLX: 1.84 (-0.04), MEET: 1.78 (+0.02), INFI: 15.13 (+0.55), CYRN: 2.83 (+0.23), APOL: 25.97 (+0.33), CJJD: 2.59 (-0.01), CRK: 6.09 (+0.46), FOLD: 8.36 (-0.11), GST: 2.89 (unch)
Stemline Therapeutics Prices $59.85 Million Public Offering of Common Stock
GlobeNewswire - Thu Jan 08, 8:05AM CST
Stemline Therapeutics, Inc. (Stemline) (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics targeting cancer stem cells (CSCs) and tumor bulk, today announced the pricing of its previously announced underwritten public offering of 3,800,000 shares of its common stock at a public offering price of $15.75 per share. Stemline has also granted the underwriters a 30-day option to purchase up to an additional 570,000 shares of common stock from Stemline. The gross proceeds to Stemline from the public offering are expected to be $59.85 million, before deducting estimated underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on January 13, 2015, subject to customary closing conditions. Stemline intends to use the net proceeds from the public offering to fund the clinical development of SL-401, SL-701, the development of its preclinical pipeline, and other general corporate purposes.
STML: 14.07 (-0.10)
Stemline Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Jan 07, 3:42PM CST
Stemline Therapeutics, Inc. (Stemline) (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics targeting cancer stem cells (CSCs) and tumor bulk, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Stemline expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering. Stemline intends to use the net proceeds from the public offering to fund the clinical development of SL-401, SL-701, the development of its preclinical pipeline and other general corporate purposes.
STML: 14.07 (-0.10)
Stemline Therapeutics In-Licenses Novel Oral Small Molecule Nuclear Transport Inhibitor Targeting XPO1
GlobeNewswire - Wed Jan 07, 3:42PM CST
Stemline Therapeutics, Inc. (Stemline) (Nasdaq:STML) announced today that it has exclusively licensed from CanBas Co., Ltd. (4575:Tokyo) the rights to develop and commercialize a novel, oral small molecule reversible inhibitor of Exportin-1 (XPO1), a nuclear transport target also known as Chromosome Region Maintenance-1 (CRM1). Stemline has acquired worldwide rights with the exception of Japan, Korea, Taiwan and China. Stemline will now refer to the compound as SL-801.
STML: 14.07 (-0.10)
Stemline Therapeutics to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Dec 29, 7:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that it will present at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 10:00 AM PT (1 PM ET). The conference will be held at the Westin St. Francis Hotel in San Francisco, CA. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
JPM: 59.67 (+0.10), STML: 14.07 (-0.10)
TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors
GlobeNewswire - Wed Dec 17, 7:30AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced the appointment of Kenneth Hoberman to the Company's Board of Directors. Mr. Hoberman is currently the Chief Operating Officer of Stemline Therapeutics, Inc. (Nasdaq:STML), a publicly-traded biotechnology company and was formerly the VP, Corporate and Business Development of Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a publicly-traded biotechnology company.
TGTX: 13.13 (-0.19), STML: 14.07 (-0.10), KERX: 11.63 (-0.60)
Stemline Therapeutics Initiates SL-401 Clinical Trial in Four Rare Myeloproliferative Neoplasms
GlobeNewswire - Tue Dec 16, 9:35AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the initiation of a clinical trial with SL-401 in four rare myeloproliferative neoplasms (MPN). SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on cancer stem cells (CSCs) and tumor bulk of a wide range of hematologic cancers. This represents the third clinical trial with SL-401, across seven oncologic indications, that Stemline has opened in the second half of 2014.
STML: 14.07 (-0.10)
Why You Shouldn't Bet Against Stemline Therapeutics (STML) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 7:39AM CST
Stemline Therapeutics is one stock that might be an intriguing choice for investors as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 57
STML: 14.07 (-0.10)
Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 0.45 (+0.06), GILD: 101.90 (+1.10), GERN: 3.03 (unch), ONTX: 2.27 (-0.02), CTIC: 2.23 (-0.02), BMY: 60.04 (+0.56), STML: 14.07 (-0.10), NVS: 102.20 (-0.17), MEIP: 5.00 (-0.04), CELGZ: 3.17 (-0.04), XLRN: 38.02 (+0.07)
Hairy Cell Leukemia - Pipeline Review, H2 2014
M2 - Tue Dec 09, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/mrscnl/hairy_cell) has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from this proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Plexxikon Inc. - Astellas Pharma Inc. - Incyte Corporation - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Biogenomics Limited For more information visit http://www.researchandmarkets.com/research/mrscnl/hairy_cell
INCY: 75.94 (+0.28), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30), ONTX: 2.27 (-0.02), GSK: 47.94 (+1.99), STML: 14.07 (-0.10)
Stemline Therapeutics Announces Multiple Preclinical Presentations Highlighting Its Pipeline of IL-3R-Directed Therapeutics at the American Society of Hematology (ASH) Annual Meeting
GlobeNewswire - Fri Dec 05, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that results from multiple ongoing preclinical studies were selected for presentation at the 2014 American Society of Hematology (ASH) Annual Meeting, to be held December 6-9, 2014 at the Moscone Center, San Francisco, CA. Investigators will present data on Stemline's portfolio of therapeutics that target the interleukin-3 receptor (IL-3R), which is overexpressed on tumor bulk and cancer stem cells (CSCs) of a wide variety of hematologic malignancies.
STML: 14.07 (-0.10)
Stemline Therapeutics beats 3Q profit forecasts
Automated Insights - Wed Nov 12, 9:15AM CST
NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Wednesday reported a third-quarter loss of $6.9 million.
STML: 14.07 (-0.10)
Stemline Therapeutics beats by $0.05
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:35AM CST
STML: 14.07 (-0.10)
Stemline Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Wed Nov 12, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended September 30, 2014 and provided a corporate update.
STML: 14.07 (-0.10)
Stemline Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Feb 04, 7:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 17 Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015 at 10:00 AM ET. The conference will be held at The Waldorf-Astoria in New York, NY. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
STML: 14.07 (-0.10)
3 Biotech Stocks You Won't Want To Miss In 2015
BPD Research - at Seeking Alpha - Fri Jan 30, 10:30AM CST
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), STML: 14.07 (-0.10)
Stemline Therapeutics Announces SL-701 Granted Orphan Drug Designation for the Treatment of Glioma
GlobeNewswire - Fri Jan 30, 7:36AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics targeting cancer stem cells (CSCs) and tumor bulk, announced today that SL-701 has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of glioma.
STML: 14.07 (-0.10)
Stemline Therapeutics (STML) Crumbles: Stock Falls by 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 7:44AM CST
Stemline Therapeutics (STML) fell nearly 10% in the last trading session amid huge volumes, continuing its recent volatile trend as it is currently trading within the volatile price range of last one month.
STML: 14.07 (-0.10)
Nasdaq stocks posting largest percentage decreases
AP - Thu Jan 08, 12:18PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ENPH: 15.15 (+0.37), PODD: 32.00 (-0.07), BWEN: 5.48 (+0.15), WATT: 9.43 (+0.01), RDEN: 16.59 (+0.90), MARPS: 11.70 (+0.10), BRID: 7.55 (-0.04), ICPT: 209.12 (+7.12), AIRT: 19.45 (+0.39), INFI: 15.13 (+0.55), JST: 5.35 (+0.14), STML: 14.07 (-0.10)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 11:47AM CST
ELOS: 10.16 (+0.07), MBII: 3.88 (+0.33), PDFS: 18.31 (+0.04), CASM: 1.36 (-0.01), PHMD: 1.68 (+0.04), EPRS: 7.67 (+0.67), BIND: 6.06 (+0.21), JOB: 0.79 (+0.01), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), ARO: 3.63 (+0.04), PODD: 32.00 (-0.07), AOI: 1.05 (+0.03), BWEN: 5.48 (+0.15), NBIX: 37.22 (+0.27), VLCCF: 4.15 (-0.06), NEFF: 10.43 (-0.04), PSTR: 4.63 (+0.14), INFI: 15.13 (+0.55), APOL: 25.97 (+0.33)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:15AM CST
NRX: 6.67 (-0.14), BIND: 6.06 (+0.21), NBG: 1.61 (+0.18), MBT: 10.36 (+0.62), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), SIG: 120.19 (+0.36), PBR: 6.98 (+0.44), NBIX: 37.22 (+0.27), PIR: 12.52 (+0.17), VLCCF: 4.15 (-0.06), CONN: 24.69 (-0.07), CYTR: 2.96 (+0.23), PLX: 1.84 (-0.04), MEET: 1.78 (+0.02), INFI: 15.13 (+0.55), CYRN: 2.83 (+0.23), APOL: 25.97 (+0.33), CJJD: 2.59 (-0.01), CRK: 6.09 (+0.46), FOLD: 8.36 (-0.11), GST: 2.89 (unch)
Stemline Therapeutics Prices $59.85 Million Public Offering of Common Stock
GlobeNewswire - Thu Jan 08, 8:05AM CST
Stemline Therapeutics, Inc. (Stemline) (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics targeting cancer stem cells (CSCs) and tumor bulk, today announced the pricing of its previously announced underwritten public offering of 3,800,000 shares of its common stock at a public offering price of $15.75 per share. Stemline has also granted the underwriters a 30-day option to purchase up to an additional 570,000 shares of common stock from Stemline. The gross proceeds to Stemline from the public offering are expected to be $59.85 million, before deducting estimated underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on January 13, 2015, subject to customary closing conditions. Stemline intends to use the net proceeds from the public offering to fund the clinical development of SL-401, SL-701, the development of its preclinical pipeline, and other general corporate purposes.
STML: 14.07 (-0.10)
Stemline Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Jan 07, 3:42PM CST
Stemline Therapeutics, Inc. (Stemline) (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics targeting cancer stem cells (CSCs) and tumor bulk, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Stemline expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the offering. Stemline intends to use the net proceeds from the public offering to fund the clinical development of SL-401, SL-701, the development of its preclinical pipeline and other general corporate purposes.
STML: 14.07 (-0.10)
Stemline Therapeutics In-Licenses Novel Oral Small Molecule Nuclear Transport Inhibitor Targeting XPO1
GlobeNewswire - Wed Jan 07, 3:42PM CST
Stemline Therapeutics, Inc. (Stemline) (Nasdaq:STML) announced today that it has exclusively licensed from CanBas Co., Ltd. (4575:Tokyo) the rights to develop and commercialize a novel, oral small molecule reversible inhibitor of Exportin-1 (XPO1), a nuclear transport target also known as Chromosome Region Maintenance-1 (CRM1). Stemline has acquired worldwide rights with the exception of Japan, Korea, Taiwan and China. Stemline will now refer to the compound as SL-801.
STML: 14.07 (-0.10)
Stemline Therapeutics to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Dec 29, 7:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that it will present at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 10:00 AM PT (1 PM ET). The conference will be held at the Westin St. Francis Hotel in San Francisco, CA. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
JPM: 59.67 (+0.10), STML: 14.07 (-0.10)
TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors
GlobeNewswire - Wed Dec 17, 7:30AM CST
TG Therapeutics, Inc. (Nasdaq:TGTX), today announced the appointment of Kenneth Hoberman to the Company's Board of Directors. Mr. Hoberman is currently the Chief Operating Officer of Stemline Therapeutics, Inc. (Nasdaq:STML), a publicly-traded biotechnology company and was formerly the VP, Corporate and Business Development of Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a publicly-traded biotechnology company.
TGTX: 13.13 (-0.19), STML: 14.07 (-0.10), KERX: 11.63 (-0.60)
Stemline Therapeutics Initiates SL-401 Clinical Trial in Four Rare Myeloproliferative Neoplasms
GlobeNewswire - Tue Dec 16, 9:35AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the initiation of a clinical trial with SL-401 in four rare myeloproliferative neoplasms (MPN). SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on cancer stem cells (CSCs) and tumor bulk of a wide range of hematologic cancers. This represents the third clinical trial with SL-401, across seven oncologic indications, that Stemline has opened in the second half of 2014.
STML: 14.07 (-0.10)
Why You Shouldn't Bet Against Stemline Therapeutics (STML) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 7:39AM CST
Stemline Therapeutics is one stock that might be an intriguing choice for investors as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 57
STML: 14.07 (-0.10)
Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 0.45 (+0.06), GILD: 101.90 (+1.10), GERN: 3.03 (unch), ONTX: 2.27 (-0.02), CTIC: 2.23 (-0.02), BMY: 60.04 (+0.56), STML: 14.07 (-0.10), NVS: 102.20 (-0.17), MEIP: 5.00 (-0.04), CELGZ: 3.17 (-0.04), XLRN: 38.02 (+0.07)
Hairy Cell Leukemia - Pipeline Review, H2 2014
M2 - Tue Dec 09, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/mrscnl/hairy_cell) has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from this proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Plexxikon Inc. - Astellas Pharma Inc. - Incyte Corporation - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Biogenomics Limited For more information visit http://www.researchandmarkets.com/research/mrscnl/hairy_cell
INCY: 75.94 (+0.28), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30), ONTX: 2.27 (-0.02), GSK: 47.94 (+1.99), STML: 14.07 (-0.10)
Stemline Therapeutics Announces Multiple Preclinical Presentations Highlighting Its Pipeline of IL-3R-Directed Therapeutics at the American Society of Hematology (ASH) Annual Meeting
GlobeNewswire - Fri Dec 05, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that results from multiple ongoing preclinical studies were selected for presentation at the 2014 American Society of Hematology (ASH) Annual Meeting, to be held December 6-9, 2014 at the Moscone Center, San Francisco, CA. Investigators will present data on Stemline's portfolio of therapeutics that target the interleukin-3 receptor (IL-3R), which is overexpressed on tumor bulk and cancer stem cells (CSCs) of a wide variety of hematologic malignancies.
STML: 14.07 (-0.10)
Stemline Therapeutics beats 3Q profit forecasts
Automated Insights - Wed Nov 12, 9:15AM CST
NEW YORK (AP) _ Stemline Therapeutics Inc. (STML) on Wednesday reported a third-quarter loss of $6.9 million.
STML: 14.07 (-0.10)
Stemline Therapeutics beats by $0.05
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:35AM CST
STML: 14.07 (-0.10)
Stemline Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Wed Nov 12, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical stage biopharmaceutical company developing novel drugs targeting cancer stem cells (CSCs) and tumor bulk, today reported financial results for the quarter ended September 30, 2014 and provided a corporate update.
STML: 14.07 (-0.10)
